Moreover, miR-142-5p treatment enhances anti-tumor immunity by blocking the PD-L1/PD-1 interaction in pancreatic cancer: miR-142-5p overexpression in tumor cells decreases PD-L1 expression, subsequently increasing IFN-γ and TNF-α levels as well as infiltrating CD4+ T lymphocytes and CD8+ T lymphocytes, while decreasing PD-1+ T lymphocytes in vivo [133]. Here, CD274 is linked to pancreatic neoplasm.